# Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

> **NCT05582018** · NA · TERMINATED · sponsor: **Techsomed Medical Technologies LTD** · enrollment: 4 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Metastatic Liver Cancer

## Interventions

- **DEVICE:** BioTraceIO 360

## Key facts

- **NCT ID:** NCT05582018
- **Lead sponsor:** Techsomed Medical Technologies LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-05
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-05-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582018, "Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05582018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*